Novo Nordisk Might Need Deals to Strengthen Drug Pipeline
Dow Jones
Aug 13
1640 GMT - Novo Nordisk's search for small deals to bolster its drug pipeline looks sensible, Berenberg analysts say. The Danish drugmaker's CEO seems bullish on the prospects for the obesity-pill market, but Novo Nordisk might need deals to add more oral medicines to maintain its lead, according to Berenberg. Novo Nordisk needs to diversify from semaglutide--the key ingredient in its blockbuster drugs Ozempic and Wegovy for diabetes and obesity--and its strong balance sheet allows it to do so, the analysts say. "As such, small molecule-focused business development seems likely," the analysts add. Berenberg cuts its recommendation on Novo Nordisk's stock to hold from buy, trimming its target price to 305 Danish kroner from 325 kroner. Shares close 2.5% lower at 299.50 kroner.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.